Rixubis (Intravenous)

Generic name:coagulation factor ix recombinant (intravenous route) [ koh-a-gyoo-LAY-shun-FAK-tor-NINE-re-KOM-bin-ant ]
Drug class:Miscellaneous coagulation modifiers

Medically reviewed by Drugs.com. Last updated on Jan 15, 2022.

Commonly used brand name(s)

In the U.S.

• Benefix
• Ixinity
• Rixubis

Available Dosage Forms:

• Powder for Solution

Therapeutic Class: Antihemophilic Agent

Uses for Rixubis

Coagulation factor IX, recombinant injection is used to treat, control, prevent, and decrease the frequency of bleeding episodes, and prevent bleeding during surgery in patients with hemophilia B (congenital Factor IX deficiency or Christmas disease).

Factor IX is a protein that is produced naturally in the body. This medicine is a man-made protein produced to replicate the naturally occurring factor IX in the body. It is used to stop bleeding by helping the blood to clot in patients with hemophilia B.

This medicine is to be given only by or under the supervision of your doctor and is available only with your doctor's prescription.

Before using Rixubis

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies have not been performed on the relationship of age to the effects of Ixinity® in children younger than 12 years of age. Safety and efficacy have not been established.

Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of BeneFIX® to prevent or decrease the frequency of bleeding episodes in children 16 years of age and older, or to treat and control bleeding episodes or prevent bleeding during surgery in children younger than 12 years of age. However, because of BeneFIX®'s toxicity, it should be used with caution and an adjustment in the dose is needed. Children should be carefully monitored during treatment.

Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of Rixubis™ in children.

Geriatric

Although appropriate studies on the relationship of age to the effects of coagulation factor IX, recombinant injection have not been performed in the geriatric population, no geriatric-specific problems have been documented to date.

Breastfeeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with medicines

Although certain medicines should not be used together at...